Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07771803 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT07771803 · ClinicalTrials.gov record · last posted 2026-08-18

A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM)

Study acronym: Soursop
StatusRecruiting
PhaseEarly Phase 1
Started2025-06-30
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
Purpose/Specific Aims The study will determine if there is a reduction in malignant cell burden when patients with relapsed and/or refractory acute myeloid leukemia (AML) or multiple myeloma (MM) consume tea made from the dried leaves of Annona muricata (Soursop). The study goal is to determine the safety and anti-neoplastic efficacy of Annona muricata tea when taken in escalating frequency over a period of 21 days by patients with relapsed/refractory AML or MM for whom there are no standard therapeutic options.
Trial Details
NCT Number NCT07771803
Lead Sponsor Roger Strair
Conditions AML (Acute Myeloid Leukemia), Multiple Myeloma Refractory
Enrollment 20 participants
Start Date 2025-06-30
Primary Completion 2026-12-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-18